...
首页> 外文期刊>BMC Genomics >Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment
【24h】

Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment

机译:使用HaloPlex靶标富集准确检测全基因组扩增和合并的癌症样品中的亚克隆单核苷酸变异体

获取原文

摘要

Background Target enrichment and resequencing is a widely used approach for identification of cancer genes and genetic variants associated with diseases. Although cost effective compared to whole genome sequencing, analysis of many samples constitutes a significant cost, which could be reduced by pooling samples before capture. Another limitation to the number of cancer samples that can be analyzed is often the amount of available tumor DNA. We evaluated the performance of whole genome amplified DNA and the power to detect subclonal somatic single nucleotide variants in non-indexed pools of cancer samples using the HaloPlex technology for target enrichment and next generation sequencing. Results We captured a set of 1528 putative somatic single nucleotide variants and germline SNPs, which were identified by whole genome sequencing, with the HaloPlex technology and sequenced to a depth of 792–1752. We found that the allele fractions of the analyzed variants are well preserved during whole genome amplification and that capture specificity or variant calling is not affected. We detected a large majority of the known single nucleotide variants present uniquely in one sample with allele fractions as low as 0.1 in non-indexed pools of up to ten samples. We also identified and experimentally validated six novel variants in the samples included in the pools. Conclusion Our work demonstrates that whole genome amplified DNA can be used for target enrichment equally well as genomic DNA and that accurate variant detection is possible in non-indexed pools of cancer samples. These findings show that analysis of a large number of samples is feasible at low cost, even when only small amounts of DNA is available, and thereby significantly increases the chances of indentifying recurrent mutations in cancer samples.
机译:背景技术靶标富集和重测序是用于鉴定与疾病相关的癌症基因和遗传变异的广泛使用的方法。尽管与全基因组测序相比具有成本效益,但许多样品的分析构成了相当大的成本,可以通过在捕获前合并样品来降低成本。可以分析的癌症样本数量的另一个限制通常是可用肿瘤DNA的数量。我们使用HaloPlex技术进行靶标富集和下一代测序,评估了全基因组扩增DNA的性能以及检测非索引化癌症样本库中亚克隆体单核苷酸变异体的能力。结果我们捕获了一组1528个假定的体细胞单核苷酸变异体和种系SNP,这些均通过HaloPlex技术通过全基因组测序进行鉴定,并测序到792–1752深度。我们发现分析的变异的等位基因部分在整个基因组扩增过程中得到了很好的保存,捕获特异性或变异调用不受影响。我们检测到一个样品中唯一存在的大多数已知单核苷酸变异体,在多达十个样品的非索引库中,等位基因分数低至0.1。我们还确定并实验验证了池中所含样品中的六个新变体。结论我们的工作表明,全基因组扩增的DNA可以与基因组DNA一样好地用于靶标富集,并且在未标引的癌症样本库中可能进行准确的变异检测。这些发现表明,即使只有少量的DNA可用,以低成本进行大量样品的分析也是可行的,从而显着增加了鉴定癌症样品中复发突变的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号